Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Aledort
L M
LM
Mount Sinai School of Medicine, New York, New York 10029-6574, USA. louis.aledort@mssm.edu
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001779:Blood Coagulation Factors / Q000009:adverse effects*; D002648:Child; D003625:Data Collection; D005167:Factor VII / Q000008:administration & dosage / Q000009:adverse effects*; D015942:Factor VIIa; D006801:Humans; D015994:Incidence; D020767:Intracranial Thrombosis / Q000139:chemically induced; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D013927:Thrombosis / Q000139:chemically induced* / Q000453:epidemiology
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa